Pulvinal Salbutamol

Quick links

Choose a section

Quick links to important sections

Advertisements

Pulvinal Salbutamol

Advertisements
Advertisements

Overview of Pulvinal Salbutamol

Quick Facts

Property Description
Active ingredient Salbutamol (INN) / Albuterol (USAN)
Form Dry Powder Inhaler (DPI)
Pharmacological class Selective beta2-adrenoceptor agonist
Common use Acute relief of breathing difficulty
Origin Synthetic compound

What Kind of Medicine is Pulvinal Salbutamol?

Pulvinal Salbutamol is classified as a bronchodilator and a prescription-only medicine, designed for inhaled therapy that provides rapid action. Its core component is the active ingredient Salbutamol (INN), a synthetic compound also known as Albuterol (USAN). The International Non-proprietary Name, Salbutamol, is officially categorized as a selective beta2-adrenoceptor agonist.

This compound functions as a short-acting agent within its class, distinguishing it from longer-acting bronchodilator analogues used for sustained management. Salbutamol's clinical effect is rapid, making it appropriate for acute, on-demand use. The rapid onset reinforces its critical role as a reliever medicine.

Composition and Delivery System: Understanding the Pulvinal Form

The term Pulvinal denotes the medicine's specific dosage form, which is a Dry Powder Inhaler (DPI) preparation delivered via the inhalation route. In this system, the medication is prepared as a metered-dose dry powder.

The high-level composition is a single-ingredient formulation, consisting of Salbutamol sulfate combined with an inert dry powder excipient, typically lactose monohydrate. This DPI delivery method is clinically recognized for optimizing localized delivery of the active substance to the lower airways.

What is the General Purpose of Salbutamol?

The general purpose of the Salbutamol component is to function as a reliever medicine by rapidly addressing the physical tightening of the airways. This utility is a direct result of the compound’s ability to promote bronchial smooth muscle relaxation.

This fast-acting effect is crucial for quickly alleviating the acute constriction of the breathing passages, known as bronchospasm. The medicine's design and mechanism align its purpose with rapidly restoring and facilitating easier airflow, such as during an acute episode of shortness of breath.

Regulatory References

  1. Albuterol - StatPearls - NCBI Bookshelf
Advertisements

What side effects are possible with Pulvinal Salbutamol?

Possible Side Effects and Safety Information

Official regulatory documents classify the possible adverse reactions of Salbutamol based on their frequency and the system affected. The safety profile is primarily structured around effects related to its pharmacological class, and these effects are categorized for clear communication.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped into categories ranging from Common to Very Rare, as defined in regulatory labels:

Classification Examples of Documented Effects
Common Tremor, Headache, Tachycardia (increased heart rate).
Uncommon Palpitations, Muscle cramps, Throat irritation.
Rare Hypersensitivity reactions (e.g., Angioedema, Collapse), Hypokalaemia (low blood potassium), Peripheral vasodilatation.
Very Rare Paradoxical bronchospasm, Cardiac arrhythmias, Lactic acidosis, Hyperactivity.

Systemic and Timing Patterns

Adverse reactions are grouped by System-Organ Class (SOC) categories, including Cardiac Disorders (e.g., Tachycardia) and Nervous System Disorders (e.g., Tremor). Documentation notes that effects such as tremor and tachycardia are often more pronounced at the start of treatment and generally diminish with continued use. Conversely, Paradoxical Bronchospasm, a serious risk of immediate worsening of breathing, is a documented event following inhalation.

Serious Reactions and Safety Constraints

Regulatory sources explicitly define specific events as Serious Adverse Reactions. These include Paradoxical Bronchospasm and severe forms of Hypersensitivity Reactions. The label also requires particular caution for administration in individuals with pre-existing conditions, specifically cardiovascular disorders (e.g., arrhythmias, severe heart failure) or hyperthyroidism. The label mandates immediate discontinuation of the medicine if paradoxical bronchospasm is observed.

Advertisements

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information

The overdose profile of Salbutamol is defined by documented excessive systemic stimulation, primarily manifesting as tachycardia, palpitations, and tremor. Other documented signs include headache, nervousness, nausea, and angina (chest pain). Physiological disturbances commonly noted in the regulatory literature are hypokalemia and metabolic acidosis (lactic acidosis).

Physiological systems affected: The overdose state involves the Cardiovascular, Musculoskeletal, and Metabolic systems.

Emergency-Response Statements and Urgent Care:

Regulators mandate that patients seek immediate medical attention for suspected overdose or the sudden onset of paradoxical bronchospasm. Urgent care is also required if the medicine fails to provide expected relief, as this may signal worsening asthma or the need for a treatment reassessment. Overdose is often a consequence of excessive use, and patients with pre-existing cardiac disease are noted as a population with increased risk for severe manifestations.

Official Overdose Statements (Severity and Management):

  • Overdose may progress to life-threatening complications, including cardiac arrhythmias, seizures, and cardiac arrest. Fatalities have been reported in association with excessive use.
  • Treatment is strictly symptomatic and supportive, as no specific antidote is known.
  • Post-overdose monitoring includes surveillance of serum potassium levels and ECG monitoring for cardiac effects.

The official documents define the overdose state through these specific clinical manifestations and underscore the importance of seeking immediate medical help to address potential life-threatening systemic escalation.

Advertisements

Therapeutic Uses of Pulvinal Salbutamol

Quick Facts: Therapeutic Areas

  • Relief of Bronchospasm: Utilized to address episodes of airway narrowing associated with certain conditions.
  • Asthma Symptoms: Employed to manage the presentation of asthma, including shortness of breath and wheezing.
  • COPD: Used in the care plan for individuals with chronic obstructive pulmonary disease.
  • Prevention: May be taken to anticipate and address symptoms potentially triggered by exercise or exposure to known irritants.

Pulvinal Salbutamol is indicated for the management of conditions where breathing is affected by the temporary narrowing of the airways. The medication is used to provide relief from symptoms associated with asthma and other chronic obstructive pulmonary disease (COPD).

The therapeutic intent of Pulvinal Salbutamol is primarily focused on addressing acute episodes where a patient experiences difficulty breathing, wheezing, or chest tightness. Its role is as a rescue or reliever agent to facilitate the passage of air within the lungs.

Furthermore, this therapeutic agent is utilized in a preventative capacity for individuals who experience symptoms following known triggers, such as physical activity or exposure to allergens. In these instances, the medication is administered prior to the anticipated event as part of a comprehensive management strategy.

Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Restriction Profile

The eligibility profile for Pulvinal Salbutamol is defined by regulatory bodies through specific contraindications and required cautions concerning a patient's medical history and physiological state. The medicine is primarily intended for use in Adults and Children aged 4 years and older who can properly use the dry powder inhaler device.

Classification Status and Population
Absolute Contraindications Prohibited for patients with hypersensitivity to salbutamol or any excipient (e.g., lactose) and for use in treating premature labour or threatened abortion (non-IV forms).
Use with Caution Required for patients with severe cardiovascular disorders, thyrotoxicosis (overactive thyroid), or diabetes mellitus. Patients with pre-existing hypokalaemia (low potassium) also require close monitoring.
Age Restriction Children under 4 years are typically not approved for general use. Some DPI devices may be unsuitable for all children under 12 years due to device flow requirements.
Conditional Use Status In pregnancy and lactation, use is conditional and not recommended unless the expected benefit to the mother outweighs any potential risk to the fetus or neonate, as safety is not established in these populations.
Advertisements

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Pulvinal Salbutamol

Category Official Regulatory Documentation Statement
Medicinal product categories with documented interactions Beta-adrenergic receptor blocking agents; Monoamine Oxidase Inhibitors (MAOIs); Tricyclic Antidepressants (TCAs); Non–Potassium-Sparing Diuretics; Other short-acting sympathomimetic aerosol bronchodilators; Adrenergic Drugs.
Specific interacting medicines (if explicitly listed) Digoxin; Epinephrine.
Mechanistic basis of interactions (only if stated in label) Functional Antagonism; Potentiation of Vascular Effects; Additive Hypokalemic/Cardiovascular Risk; Reduction of Serum Levels.
Timing-based interaction rules (if applicable) Mandatory two-week separation period for discontinuation of MAOIs or TCAs; Prohibited concomitant use with other short-acting sympathomimetics.

Interaction Classifications (High-Level)

Classification Regulatory Status
Interaction severity classification Contraindicated/Prohibited Combinations; Clinically Significant Interaction requiring caution; Avoid Concurrent Use.
Regulatory basis U.S. Food and Drug Administration (FDA) and equivalent government regulatory documents.

Resulting Interaction Structure

Official Interaction Statements:

  • Beta-adrenergic receptor blocking agents may block the pulmonary effect, risking severe bronchospasm (Functional Antagonism).
  • MAOIs and TCAs may potentiate the effect on the vascular system, requiring administration with extreme caution or a mandatory two-week separation period.
  • Non–Potassium-Sparing Diuretics carry an additive risk of worsening hypokalemia and electrocardiographic changes.
  • Co-administration with Digoxin may result in a documented decrease in serum Digoxin levels.
  • Concomitant use with other short-acting sympathomimetic aerosol bronchodilators or Epinephrine is formally prohibited.
  • Hypersensitivity to milk proteins is an interaction-related restriction for dry powder formulations containing lactose excipient.

Connection to the overall interaction profile (2–4 sentences): The regulatory interaction profile is defined by pharmacodynamic restrictions that prohibit co-administration with agents having similar sympathomimetic effects or opposing antagonistic effects. This structure mandates specific timing rules for discontinuation of certain antidepressants and outlines cautions for combined use with diuretics and the need for monitoring co-administered Digoxin levels. The constraints are based on documented outcomes of functional antagonism, potentiation, and additive systemic risk.

Advertisements

Mechanism of Action

Pulvinal Salbutamol (salbutamol sulfate) is a short-acting selective beta2-adrenergic receptor agonist. Its pharmacodynamic action commences with the molecule binding to and activating beta2-adrenergic receptors, which are G-protein coupled receptors ( G s type) primarily located on the smooth muscle cells of the bronchial tree.

Activation of the receptor triggers the dissociation of the G s protein subunit, which subsequently activates the enzyme adenylyl cyclase. Adenylyl cyclase catalyzes the conversion of ATP to the second messenger, cyclic adenosine monophosphate ( cAMP), leading to a rapid increase in its intracellular concentration.

The elevated cAMP levels activate Protein Kinase A ( PKA). PKA then phosphorylates specific intracellular targets, notably resulting in a decrease in the concentration of intracellular calcium ions ( Ca^2+). This reduction is achieved by promoting Ca^2+ sequestration and inhibiting MLCK. The decrease in free Ca^2+ inhibits the contractile mechanism of the smooth muscle, resulting in the relaxation of the airway musculature and subsequent bronchodilation.

Advertisements

Dosage and Administration Information

Pulvinal Salbutamol is administered exclusively by oral inhalation using the specific Dry Powder Inhaler (DPI) device. Official guidelines establish precise dosing and frequency constraints that must be followed to ensure correct usage.

Official Dosing and Frequency

Regimen Type Standard Adult Dose Frequency and Interval Constraint
Acute Relief 100 micrograms to 200 micrograms Used as-needed; 4 hours minimum interval between doses.
Symptom Prevention 200 micrograms Must be administered 10 to 15 minutes prior to trigger.
Maximum Daily Use Not to exceed 8 inhalations (800 micrograms) in any 24 hour period for on-demand use.

Administration Requirements

Route of Administration: Oral inhalation only, delivering the metered dose of dry powder directly to the airways.

Age-Group Rules:

  • Pediatric (4 to 11 years): The starting dose for both acute relief and prevention is 100 micrograms, which may be increased to 200 micrograms if required. For continuous management, the maximum is 200 micrograms four times daily.
  • Older Adults: No specific dose adjustment is required, following the same guidelines as the general adult population.

Special Procedural Conditions:

  • Inhalation should be performed from a sitting or standing position to optimize drug delivery.
  • Administration by children requires adult supervision to ensure correct technique.

Reliance on the need for increased or frequent use of this medicine is an official sign of deteriorating control and necessitates a professional reassessment of the treatment plan.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Core Findings

Research has investigated the drug’s role in managing the target condition of bronchospasm associated with asthma. Studies examined whether the dry powder formulation was associated with changes in the severity and duration of symptoms in patients.

  • Key Trial Data: Randomized controlled trials have investigated the impact of inhaled salbutamol on disease activity over defined periods. Observational studies and meta-analyses have also evaluated the drug's role in the long-term study of inflammation and airway responsiveness.
  • Safety Profile: Safety data were collected on trial participants, with commonly reported adverse events including palpitations, tremor, and nervousness, which are related to systemic beta-2 receptor activation. Some research suggests that individuals with specific co-existing conditions were excluded from or showed different responses in the evaluated trials.
  • Pharmacodynamics: The meta-analysis summarized findings regarding the drug's impact on clinical outcomes. Research reports have included discussions of potential biological actions, such as the relaxation of bronchial smooth muscle, which improves airflow.

Investigating Symptom Onset

A study on the formulation investigated the time to onset of response following inhalation. The analysis tracked patient self-reported time-to-first-response. The median time observed was typically within 5 to 15 minutes among participants receiving the investigational treatment.

Long-Term Research and Comparisons

Research reports have contained data comparing findings between the investigational drug and other treatments, including combined therapies. Analysis of registry data has focused on outcomes, such as recurrence rates and asthma control, over extended periods. Recent evidence from clinical practice guidelines indicates that short-acting beta-agonists (SABAs) like salbutamol are no longer recommended as monotherapy for asthma and are primarily utilized as reliever or rescue medication.

Key Studies & References

  1. Global Strategy for Asthma Management and Prevention, 2023. Updated May 2023 (GINA Guidelines)
  2. Use of dry powder inhalers in acute exacerbations of asthma and COPD (CRD summary)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Pulvinal Salbutamol (FAQ)

Q: Is Pulvinal Salbutamol the same as a standard blue inhaler?

A: Pulvinal Salbutamol is categorized as a Dry Powder Inhaler (DPI) formulation containing the active ingredient salbutamol. Official documents classify salbutamol as a short-acting bronchodilator, which is the class of medicine found in most standard blue reliever inhalers. The primary differences relate to the delivery device and the medicine's form (a powder versus a spray).

Q: Why is Pulvinal Salbutamol a powder instead of a spray?

A: The Dry Powder Inhaler (DPI) formulation is often selected to help ensure the optimal delivery of the medicine directly into the lungs. This design may simplify the process for some users as it does not require the precise hand-breath coordination needed for some traditional spray inhalers. This medicine is also breath-actuated, meaning it releases the powder automatically when you inhale.

Q: How long do the effects of Pulvinal Salbutamol usually last?

A: According to official product information, the duration of action for the inhaled salbutamol component is described as typically lasting four to six hours in the majority of patients. Salbutamol is classified as a short-acting bronchodilator, providing prompt, though temporary, relief from breathing difficulty, as classified in product documents.

Q: Is it safe to use Pulvinal Salbutamol every day?

A: Official guidance notes that this medicine may be used daily for symptom prevention or on an as-needed basis for relief. Regulatory documents specify that an increased need to use the inhaler more frequently or in greater amounts is considered a sign that the underlying condition may be worsening. If this occurs, a professional reassessment of the treatment plan is officially advised.

Q: What happens if I accidentally use Pulvinal Salbutamol when I don't need it?

A: Regulatory documents caution against exceeding the recommended dosage for this medicine. Overuse may lead to symptoms such as tremor, headache, or an increased heart rate (tachycardia). Official documents caution against exceeding the recommended maximum. Should side effects occur, consultation with a healthcare professional is advised.

Q: Do you get withdrawal symptoms if you stop using Pulvinal Salbutamol?

A: Official regulatory documents do not define a specific withdrawal syndrome associated with this medicine. However, because this product helps manage underlying breathing conditions, stopping the treatment suddenly without professional guidance may be associated with the return or worsening of the underlying symptoms.

Q: Are there any food or drink restrictions when using Pulvinal Salbutamol?

A: According to official health and drug information, there are no generally required restrictions concerning food or non-alcoholic drinks when using inhaled salbutamol products.

Q: Can I take pain relievers like ibuprofen with Pulvinal Salbutamol?

A: Official guidance advises patients to consult with a healthcare professional before taking any new medicine, including common over-the-counter pain relievers. This is because official guidance notes that some individuals with the underlying condition have reported a potential worsening of their breathing symptoms after taking certain painkillers.

Q: Does Pulvinal Salbutamol interact with caffeine?

A: Official safety information advises caution when using this medicine alongside other substances that affect the heart rate or blood pressure. Salbutamol and caffeine are both substances known to stimulate the cardiovascular system, and this combination may be associated with additive effects on the cardiovascular system.

Q: Are there any known interactions between Pulvinal Salbutamol and common cold medicines?

A: Many common cold and flu medicines contain active ingredients classified as adrenergic drugs or sympathomimetics. The regulatory interaction profile cautions against or prohibits the combined use of salbutamol with these types of drugs. This is due to the potential for the medicines to cause additive effects on the cardiovascular system.

Q: Is Pulvinal Salbutamol safe for people with high blood pressure?

A: Regulatory documents specify that this medicine should be used with caution in individuals with pre-existing cardiovascular conditions, including high blood pressure. This caution is advised because salbutamol may increase heart rate (tachycardia) or blood pressure, effects which may be more relevant for individuals with pre-existing cardiovascular conditions.

Q: Is Pulvinal Salbutamol ever prescribed for coughs not related to asthma?

A: The regulatory indications for Pulvinal Salbutamol define its purpose as a bronchodilator for the relief of symptoms related to bronchospasm (airway tightening). The label limits its defined uses to the management of asthma and other related chest illnesses where bronchodilation is indicated.

Q: Why might a doctor prescribe the Pulvinal device over other inhaler types?

A: Regulatory documents note that Dry Powder Inhalers (DPIs) may be selected because they are breath-actuated. This design reduces the need for the precise hand-breath coordination required with some other types of inhaler devices.

Q: Has Pulvinal Salbutamol been studied in exercise-induced breathing problems?

A: Official regulatory documents state that salbutamol is indicated for the prevention of asthma symptoms. This includes symptoms that may be brought on by specific known triggers, such as exercise.

Q: What is the difference between Pulvinal Salbutamol and regular Salbutamol inhalers?

A: Pulvinal Salbutamol refers to a specific Dry Powder Inhaler (DPI) device that delivers the medicine as a fine powder. The term 'regular' often refers to older, pressurized metered-dose inhalers (MDIs), which deliver the medicine as a spray using a propellant. Both delivery systems contain the same active ingredient, salbutamol, as noted in product labels.

Q: Does Pulvinal Salbutamol contain steroids?

A: No, official documentation classifies Pulvinal Salbutamol as a selective beta2-adrenoceptor agonist. This means it is a type of bronchodilator designed to relax the airways. It is not a corticosteroid (steroid) medicine.

Q: Can Pulvinal Salbutamol cause difficulty sleeping?

A: Official safety documentation lists difficulty sleeping, sometimes described as insomnia or disrupted sleep patterns, as a documented adverse reaction to salbutamol.

Q: Does Pulvinal Salbutamol show up on drug tests?

A: According to official metabolism data, the majority of a salbutamol dose is reported to be excreted within 72 hours of administration. While the compound is detectable through specific testing procedures, its presence may be relevant to testing protocols only if the concentration exceeds pre-defined thresholds set by sporting or other regulatory bodies.

Q: Is the powder meant to feel like it’s going into my lungs?

A: Official guidance for Dry Powder Inhalers notes that the particles are extremely fine, and it is typical for the user to not taste or feel the powder as it is inhaled. Because of this, feeling the powder is not necessary to confirm the medication has been administered.

Q: Why do official documents specify that Pulvinal Salbutamol should be used with caution in certain conditions?

A: Caution is specified because the medicine is known to stimulate the cardiovascular system due to its pharmacological class. For individuals with conditions like severe heart disorders or hyperthyroidism, this stimulation may result in adverse effects such as an increased heart rate or changes in blood pressure, which may require closer oversight by a healthcare professional.

Q: Is there a risk of developing a tolerance to Pulvinal Salbutamol over time?

A: Scientific research has investigated the possibility of developing tolerance to the effect of salbutamol with consistent use. Official regulatory guidance advises that if the effectiveness of the usual dose diminishes or the frequency of required use increases, professional reassessment is advised.

Q: Can Pulvinal Salbutamol affect lab test results?

A: Official safety documentation notes that salbutamol can cause transient changes in laboratory values as a documented adverse reaction. The most notable changes include a decrease in serum potassium levels, known as hypokalaemia, or an increase in blood glucose levels.

Q: What is the purpose of the dose counter on the Pulvinal device?

A: The purpose of the dose counter on the device is to provide a clear, visual indication of the amount of medication remaining. This feature assists the user in tracking their usage and noting when the device is near empty.

Q: Does the medicine come out if I shake the device before using it?

A: Instructional guidance for this type of device typically advises against shaking the device before use, as this action may interfere with the proper loading or measurement of the powder dose.

Q: What kind of adverse reaction is 'paradoxical bronchospasm'?

A: Official safety documentation defines paradoxical bronchospasm as a serious, immediate adverse reaction. This reaction is characterized by an unexpected and sudden worsening of breathing difficulties or wheezing that occurs immediately after inhaling the medicine.

Advertisements

How should Pulvinal Salbutamol be stored and disposed of?

How to Store and Dispose of Pulvinal Salbutamol

The storage and disposal of Pulvinal Salbutamol (Dry Powder Inhaler) must strictly follow official regulatory requirements to ensure product stability and safety.

Official Storage Requirements

Condition Requirement
Temperature Do not store above 30 C. Do not refrigerate or freeze.
Protection Store in a dry place and protect from light and direct heat.
Container Keep the container tightly closed and always replace the cap after use.
Safety Keep the medicine out of the reach and sight of children.
Stability Do not use the product after the stated expiry date.

Disposal

Regulatory documents mandate that the product must not be disposed of via wastewater or regular household waste. Unused or expired medication should be returned to a pharmacist for proper disposal in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pulvinal Salbutamol found in:

A-Z Index: